【Objective】 To evaluate the suitability of current quality standard for end-stage hemolytic rate required by Quality Requirements for Whole Blood and Blood Components in Taiyuan through a 5- year retrospective analysis of leukocyte-reduced RBCs in additive solution in Taiyuan Blood Center. 【Methods】 A total of 240 packs of leukocyte-reduced RBCs in additive solution were collected from January 2007 to December 2021. Hb concentration, hematocrit(Hct) and free Hb in supernatant at end-stage were detected to measure the hemolytic rate. And the hemolytic rate was then compared with the current standard(0.8%) to analyze whether statistical differences existed. 【Results】 The hemolytic rate of leukocyte-reduced RBCs in additive solution were 0.109±0.123 in 2017, 0.113±0.085 in 2018, 0.121±0.076 in 2019, 0.101±0.057 in 2020, and 0.128±0.089 in 2021, with no significant difference among each other (P>0.05). And 97.5% of the products showed an end-stage hemolytic rate below 0.4%, 0.83% among 0.6%~0.7%, and none over the standard of 0.8%. 【Conclusion】 The current national standard for end-stage hemolytic rate of leukocyte-reduced RBCs in additive solution might not be suitable for blood quality control in Taiyuan, and a much stricter criteria should be considered.

Objective:To explore the factors influencing the severity and prognosis of vancomycin-associated acute kidney injury (AKI).Methods:Case reports on vancomycin-associated AKI were collected by searching the relevant databases home and abroad up to June 2020. Patients′ relevant information such as general condition, underlying diseases, infecting species, treatment of vancomycin, baseline serum creatinine (Scr), baseline estimated glomerular filtration rate (eGFR), time from medication to onset of AKI, Scr elevation rate, eGFR decline rate, management of AKI, and outcomes were recorded and descriptively analyzed. The influence factors of the rates of Scr elevation and eGFR decline in patients were analyzed using robust regression method and the influence factors of the prognosis of vancomycin-associated AKI were analyzed by comparing the main clinical features of patients with basic recovery and improvement of Scr level.Results:A total of 81 reports involving 109 patients were enrolled in the analysis, including 65 males and 44 females, aged from 1 to 84 years with a median age of 49 years, of which 20 were ≤15 years old and 61 (56.0%) suffered from underlying chronic diseases. The median daily dose of vancomycin was 2.00 (0.75, 6.00) g in 89 adult patients and 40.0 (10.3, 240.0) mg/kg in 20 pediatric patients. The median time from medication to onset of AKI was 7 (1, 135) days, and 80 (73.4%) occurred within 14 days after first medication. Seventy-five patients (68.8%) had concomitant use of drugs with potential nephrotoxicity. The median value of peak Scr was 408 (53, 1 000) μmol/L, and the median eGFR was 44.3 (4.2, 280.7) ml/(min·1.73 m 2) after developing AKI. Steady-state trough concentration of vancomycin was recorded in 57 patients, which was 46.2 (11.8,284.0) mg/L before or at onset of AKI. Except 4 patients died and 1 patient was lost to follow-up, the Scr level basically recovered in 50 patients, were improved in 51 patients, and did not recover in 3 patients, which required continuous renal replacement therapy. Robust regression analysis showed that the trough concentration of vancomycin and the number of concomitant nephrotoxic drugs were significantly correlated with the rates of Scr elevation and eGFR decline after AKI (all P<0.05). The age and peak Scr in patients with basic recovery of renal function were significantly lower than those in patients with improved renal function (all P<0.001), while the lowest eGFR value was significantly higher( P=0.036). Conclusions:Patients with higher trough concentration of vancomycin and more nephrotoxic drugs would have greater elevation of Scr and the decline of eGFR. Older age, higher Scr peak value, and lower eGFR was associated with worse recovery of the renal function.

Objective:To explore the factors influencing the severity and prognosis of vancomycin-associated acute kidney injury (AKI).Methods:Case reports on vancomycin-associated AKI were collected by searching the relevant databases home and abroad up to June 2020. Patients′ relevant information such as general condition, underlying diseases, infecting species, treatment of vancomycin, baseline serum creatinine (Scr), baseline estimated glomerular filtration rate (eGFR), time from medication to onset of AKI, Scr elevation rate, eGFR decline rate, management of AKI, and outcomes were recorded and descriptively analyzed. The influence factors of the rates of Scr elevation and eGFR decline in patients were analyzed using robust regression method and the influence factors of the prognosis of vancomycin-associated AKI were analyzed by comparing the main clinical features of patients with basic recovery and improvement of Scr level.Results:A total of 81 reports involving 109 patients were enrolled in the analysis, including 65 males and 44 females, aged from 1 to 84 years with a median age of 49 years, of which 20 were ≤15 years old and 61 (56.0%) suffered from underlying chronic diseases. The median daily dose of vancomycin was 2.00 (0.75, 6.00) g in 89 adult patients and 40.0 (10.3, 240.0) mg/kg in 20 pediatric patients. The median time from medication to onset of AKI was 7 (1, 135) days, and 80 (73.4%) occurred within 14 days after first medication. Seventy-five patients (68.8%) had concomitant use of drugs with potential nephrotoxicity. The median value of peak Scr was 408 (53, 1 000) μmol/L, and the median eGFR was 44.3 (4.2, 280.7) ml/(min·1.73 m 2) after developing AKI. Steady-state trough concentration of vancomycin was recorded in 57 patients, which was 46.2 (11.8,284.0) mg/L before or at onset of AKI. Except 4 patients died and 1 patient was lost to follow-up, the Scr level basically recovered in 50 patients, were improved in 51 patients, and did not recover in 3 patients, which required continuous renal replacement therapy. Robust regression analysis showed that the trough concentration of vancomycin and the number of concomitant nephrotoxic drugs were significantly correlated with the rates of Scr elevation and eGFR decline after AKI (all P<0.05). The age and peak Scr in patients with basic recovery of renal function were significantly lower than those in patients with improved renal function (all P<0.001), while the lowest eGFR value was significantly higher( P=0.036). Conclusions:Patients with higher trough concentration of vancomycin and more nephrotoxic drugs would have greater elevation of Scr and the decline of eGFR. Older age, higher Scr peak value, and lower eGFR was associated with worse recovery of the renal function.

Objective To explore whether PPARαtransgenic mice are more sensitive animal models in the evalua-tion of toxicity of PPARαagonists.Methods Twenty-eight 8-week old PPARαtransgenic mice (Tg) and 28 C57BL/6J mice (WT) with half males and half females were randomly divided into high dose group (400 mg/kg of clofibrate), low dose group (30 mg/kg of clofibrate) and solvent control group (10%sodium carboxymethyl cellulose ).The time of gavage administration lasted 28 days.The blood biochemistry , organ coefficient and pathological changes of the heart , liver, kid-neyweretestedafterthedrugadministration.Thegrowthofmicewasalsorecorded.Results ①Bloodbiochemistry:Com-pared with the WT male administration group , in the Tg male administration group , the levels of blood creatinine ( CREA) and aspartate aminotransferase (AST) were markedly increased (P<0.01, P<0.05).② Organ coefficient: Compared with the Tg control group, the kidney coefficients of Tg administration group were significantly increased (P<0.01,P<0.05).③Histopathology:Compared with the WT administration group , the pathological damages of liver and kidney were more serious in the Tg administration group .Conclusions Compared with C57BL/6J mouse, PPARαtransgenic mice are more sensitive in evaluation of hepatotoxicity and nephrotoxicity of PPARαagonists .It is a new animal model .